Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan in advanced renal cell carcinoma in China
NCT05030506Phase 1Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2021
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of belzutifan in renal cell carcinoma (RCC) (2 arms), sponsored by Merck & Co. Primary endpoints: Dose-Limiting Toxicities at 21 days, Adverse Events at 68 months and 11 more. Started Oct 2021; status: active, not recruiting.
02
Drugs
belzutifan
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05030506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05030506.